Compounds that inhibit Mcl-1 protein


Ontology type: sgo:Patent     


Patent Info

DATE

2020-11-03T00:00

AUTHORS

HARRINGTON PAUL E , ASHTON KATE , BROWN SEAN P , KALLER MATTHEW R , KOHN TODD J , LANMAN BRIAN ALAN , LI KEXUE , LI YUNXIAO , LOW JONATHAN D , MINATTI ANA ELENA , PICKRELL ALEXANDER J , STEC MARKIAN M , TAYGERLY JOSHUA

ABSTRACT

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer. More... »

Related SciGraph Publications

  • 2008-12. BCL-2 family antagonists for cancer therapy in NATURE REVIEWS DRUG DISCOVERY
  • 2008-12-16. Mcl-1 is a potential therapeutic target in multiple types of cancer in CELLULAR AND MOLECULAR LIFE SCIENCES
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/03", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0305", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "name": "HARRINGTON PAUL E", 
            "type": "Person"
          }, 
          {
            "name": "ASHTON KATE", 
            "type": "Person"
          }, 
          {
            "name": "BROWN SEAN P", 
            "type": "Person"
          }, 
          {
            "name": "KALLER MATTHEW R", 
            "type": "Person"
          }, 
          {
            "name": "KOHN TODD J", 
            "type": "Person"
          }, 
          {
            "name": "LANMAN BRIAN ALAN", 
            "type": "Person"
          }, 
          {
            "name": "LI KEXUE", 
            "type": "Person"
          }, 
          {
            "name": "LI YUNXIAO", 
            "type": "Person"
          }, 
          {
            "name": "LOW JONATHAN D", 
            "type": "Person"
          }, 
          {
            "name": "MINATTI ANA ELENA", 
            "type": "Person"
          }, 
          {
            "name": "PICKRELL ALEXANDER J", 
            "type": "Person"
          }, 
          {
            "name": "STEC MARKIAN M", 
            "type": "Person"
          }, 
          {
            "name": "TAYGERLY JOSHUA", 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/nrd2658", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1030857223", 
              "https://doi.org/10.1038/nrd2658"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00018-008-8637-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1023498818", 
              "https://doi.org/10.1007/s00018-008-8637-6"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2020-11-03T00:00", 
        "description": "

    Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I,

    \n

    \"embedded
    \nor a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.\n

    ", "endDate": "2038-03-28", "id": "sg:patent.US-10821115-B2", "name": "Compounds that inhibit Mcl-1 protein", "recipient": [ { "id": "http://www.grid.ac/institutes/grid.417886.4", "type": "Organization" } ], "sameAs": [ "https://app.dimensions.ai/details/patent/US-10821115-B2" ], "sdDataset": "patents", "sdDatePublished": "2022-10-01T07:03", "sdLicense": "https://scigraph.springernature.com/explorer/license/", "sdPublisher": { "name": "Springer Nature - SN SciGraph project", "type": "Organization" }, "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/patent/patent_25.jsonl", "type": "Patent" } ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/patent.US-10821115-B2'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/patent.US-10821115-B2'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/patent.US-10821115-B2'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/patent.US-10821115-B2'


     

    This table displays all metadata directly associated to this object as RDF triples.

    82 TRIPLES      15 PREDICATES      18 URIs      9 LITERALS      2 BLANK NODES

    Subject Predicate Object
    1 sg:patent.US-10821115-B2 schema:about anzsrc-for:03
    2 anzsrc-for:0305
    3 schema:author Nbb49fc73adf94d6da1e3231f2a4cf3b8
    4 schema:citation sg:pub.10.1007/s00018-008-8637-6
    5 sg:pub.10.1038/nrd2658
    6 schema:datePublished 2020-11-03T00:00
    7 schema:description <p id="p-0001" num="0000">Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I,</p> <p id="p-0002" num="0000"><chemistry id="CHEM-US-00001" num="00001"><img id="EMI-C00001" he="44.37mm" wi="70.78mm" file="US10821115-20201103-C00001.TIF" alt="embedded image" img-content="chem" img-format="tif" orientation="portrait" inline="no"/><attachments><attachment idref="CHEM-US-00001" attachment-type="cdx" file="US10821115-20201103-C00001.CDX"/><attachment idref="CHEM-US-00001" attachment-type="mol" file="US10821115-20201103-C00001.MOL"/></attachments></chemistry><br/> or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer. </p>
    8 schema:endDate 2038-03-28
    9 schema:name Compounds that inhibit Mcl-1 protein
    10 schema:recipient grid-institutes:grid.417886.4
    11 schema:sameAs https://app.dimensions.ai/details/patent/US-10821115-B2
    12 schema:sdDatePublished 2022-10-01T07:03
    13 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    14 schema:sdPublisher N587991f8337c4dac89a1c571df190759
    15 sgo:license sg:explorer/license/
    16 sgo:sdDataset patents
    17 rdf:type sgo:Patent
    18 N2c0d18a6f8a744958ea653236c252340 schema:name LI YUNXIAO
    19 rdf:type schema:Person
    20 N46c0c540dcce4b979cced9a6883aeb6a rdf:first Ndadd92edfa9b4c34b78491fa6975f3f0
    21 rdf:rest rdf:nil
    22 N56af520d2a8643d3a408a6569925be66 schema:name HARRINGTON PAUL E
    23 rdf:type schema:Person
    24 N587991f8337c4dac89a1c571df190759 schema:name Springer Nature - SN SciGraph project
    25 rdf:type schema:Organization
    26 N68cbf6b4114d487aacc1ed932fa12eab rdf:first N7010151b81284af1a3a2fa951df2d027
    27 rdf:rest Ne9dc202283c64172a2bd3bcfa4ba80de
    28 N6a2d87efbf0e473b9d26586d70f81380 schema:name LANMAN BRIAN ALAN
    29 rdf:type schema:Person
    30 N7010151b81284af1a3a2fa951df2d027 schema:name LI KEXUE
    31 rdf:type schema:Person
    32 N70cb04689ad24078a7515923aaae1a7b rdf:first N8ef86cbbc0a947598c5b53ba5d581d93
    33 rdf:rest Nf68355f22f224d559e7e759e1e20b61c
    34 N774eb19c70164bc1a4dda1a941979d71 rdf:first N9b595e579a144367b860fcef5042735d
    35 rdf:rest N70cb04689ad24078a7515923aaae1a7b
    36 N87fe77594a5a4e229ff376ee125a66cc rdf:first N8d3c4ae98f49477281043d8e8d4bf2d6
    37 rdf:rest Na32fe0a25b364d50b274674c0739d30c
    38 N8d3c4ae98f49477281043d8e8d4bf2d6 schema:name KALLER MATTHEW R
    39 rdf:type schema:Person
    40 N8ef86cbbc0a947598c5b53ba5d581d93 schema:name MINATTI ANA ELENA
    41 rdf:type schema:Person
    42 N95d83620f23b4a7fb7a3e8557f630b17 schema:name KOHN TODD J
    43 rdf:type schema:Person
    44 N9b595e579a144367b860fcef5042735d schema:name LOW JONATHAN D
    45 rdf:type schema:Person
    46 Na32fe0a25b364d50b274674c0739d30c rdf:first N95d83620f23b4a7fb7a3e8557f630b17
    47 rdf:rest Nde615b1e206d4aa78fac5bb8206f11e2
    48 Nb5024e8499a14b3bb3dc36d44d64448c schema:name PICKRELL ALEXANDER J
    49 rdf:type schema:Person
    50 Nbb49fc73adf94d6da1e3231f2a4cf3b8 rdf:first N56af520d2a8643d3a408a6569925be66
    51 rdf:rest Nf1e047f4e6ba494696b61da1798e2e84
    52 Ncc0eb53aebe041f2bf0081a2a38b6639 rdf:first Ndb6d1dfd78fc473d9bdbe1042af74546
    53 rdf:rest N87fe77594a5a4e229ff376ee125a66cc
    54 Nd609365eaa1e40a18338c644a42ffcf7 rdf:first Ne7ffec2c8a4e4f358a43d1eac4361b72
    55 rdf:rest N46c0c540dcce4b979cced9a6883aeb6a
    56 Ndadd92edfa9b4c34b78491fa6975f3f0 schema:name TAYGERLY JOSHUA
    57 rdf:type schema:Person
    58 Ndb6d1dfd78fc473d9bdbe1042af74546 schema:name BROWN SEAN P
    59 rdf:type schema:Person
    60 Nde615b1e206d4aa78fac5bb8206f11e2 rdf:first N6a2d87efbf0e473b9d26586d70f81380
    61 rdf:rest N68cbf6b4114d487aacc1ed932fa12eab
    62 Ne7ffec2c8a4e4f358a43d1eac4361b72 schema:name STEC MARKIAN M
    63 rdf:type schema:Person
    64 Ne9dc202283c64172a2bd3bcfa4ba80de rdf:first N2c0d18a6f8a744958ea653236c252340
    65 rdf:rest N774eb19c70164bc1a4dda1a941979d71
    66 Nf1e047f4e6ba494696b61da1798e2e84 rdf:first Nfeab30368cc54cd5b87e80143c6f3069
    67 rdf:rest Ncc0eb53aebe041f2bf0081a2a38b6639
    68 Nf68355f22f224d559e7e759e1e20b61c rdf:first Nb5024e8499a14b3bb3dc36d44d64448c
    69 rdf:rest Nd609365eaa1e40a18338c644a42ffcf7
    70 Nfeab30368cc54cd5b87e80143c6f3069 schema:name ASHTON KATE
    71 rdf:type schema:Person
    72 anzsrc-for:03 schema:inDefinedTermSet anzsrc-for:
    73 rdf:type schema:DefinedTerm
    74 anzsrc-for:0305 schema:inDefinedTermSet anzsrc-for:
    75 rdf:type schema:DefinedTerm
    76 sg:pub.10.1007/s00018-008-8637-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023498818
    77 https://doi.org/10.1007/s00018-008-8637-6
    78 rdf:type schema:CreativeWork
    79 sg:pub.10.1038/nrd2658 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030857223
    80 https://doi.org/10.1038/nrd2658
    81 rdf:type schema:CreativeWork
    82 grid-institutes:grid.417886.4 schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...